Search / Trial NCT00002107

A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients

Launched by CHIRON CORPORATION · Aug 30, 2001

Trial Information

Current as of December 07, 2024

Completed

Keywords

Interleukin 2 Acquired Immunodeficiency Syndrome Aids Related Complex

ClinConnect Summary

Patients will receive subcutaneous Proleukin, and the MTD will be determined.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Patients must have:
  • Documented HIV infection by ELISA and Western blot.
  • CD4 count \> 200 cells/mm3.
  • Required:
  • FDA-approved antiretroviral therapy for at least 2 months prior to study entry.

About Chiron Corporation

Chiron Corporation, a pioneering biotechnology company, specializes in the development and commercialization of innovative therapeutic solutions and diagnostic products. With a strong focus on infectious diseases and cancer, Chiron leverages advanced research and development to address unmet medical needs. The company is committed to clinical excellence and adheres to the highest standards of regulatory compliance, ensuring that its trials are conducted with integrity and scientific rigor. Through collaboration with healthcare professionals and academic institutions, Chiron Corporation strives to enhance patient outcomes and contribute to the advancement of medical science.

Locations

San Francisco, California, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials